Research

Hormonal

Non-peptide small molecule agonists targeting the GLP-1 receptor orthosteric site can achieve binding affinities and stability comparable to or exceeding existing peptide-based GLP-1RAs, suggesting a viable mechanism for oral administration.

This paper does not offer a current treatment but identifies potential oral drug candidates. It suggests that future oral GLP-1 medications may exist that are as effective as current injectables, addressing the common desire to avoid injections.

LimitedSupportsLOW confidence
Among the studied compounds—especially hits 1, 5, and 9—possessed strong and stable interactions with critical amino acid residues such as TRP-203, PHE-381, and GLN-221 at the active site of the 6X1A-substrate along with favorable pharmacokinetic profiles... Specifically, hit 9 possessed the best docking score with a ∆G_bind value of −102.78 kcal/mol, surpassing even the control compound in binding affinity.
Mansour S. Alturki et al. · International Journal of Molecular Sciences · 2025

Why this rating

The study is purely in silico (virtual screening and molecular dynamics); no wet-lab or clinical data is presented.

Source

Structure-Based Discovery of Orthosteric Non-Peptide GLP-1R Agonists via Integrated Virtual Screening and Molecular Dynamics

Mansour S. Alturki et al. · International Journal of Molecular Sciences · 2025

DOI 10.3390/ijms26136131

mechanism_onlyCited 4×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →